Table 1.
Antithrombotic medication at discharge in relation to characteristics of the study population
| Distribution of antithrombotic medication at discharge by characteristics of study population | |||||
|---|---|---|---|---|---|
| Description | Total number of patients in each category | DAPT (n=8593) | SAPT (n=899) | Anticoagulants (n=537) | p Value |
| Age, years; mean (SD) | 61 (12) | 64 (12) | 67 (13) | <0.0001 | |
| Group, years; n (%) | <0.0001 | ||||
| <50 | 1691 | 1517 (89.7) | 118 (7.0) | 56 (3.3) | |
| 50–59 | 2821 | 2523 (89.4) | 206 (7.3) | 92 (3.3) | |
| 60–69 | 2794 | 2386 (85.4) | 271 (9.7) | 137 (4.9) | |
| 70–79 | 1962 | 1558 (79.4) | 226 (11.5) | 178 (9.1) | |
| ≥80 | 760 | 608 (80.0) | 78 (10.3) | 74 (9.7) | |
| Female, n (%) | 2467 | 2011 (81.5) | 295 (11.9) | 161 (6.5) | <0.0001 |
| Region, n (%) | <0.0001 | ||||
| Northern Europe | 3526 | 3008 (85.3) | 283 (8.0) | 235 (6.7) | |
| Southern Europe | 2290 | 1958 (89.4) | 135 (6.2) | 97 (4.4) | |
| Eastern Europe | 2291 | 1954 (85.3) | 224 (9.8) | 113 (4.9) | |
| Latin America | 2022 | 1673 (82.7) | 257 (12.7) | 92 (4.6) | |
| Centre type, n (%) | 0.0002 | ||||
| University general | 3930 | 3370 (85.8) | 362 (9.2) | 198 (5.0) | |
| Non-university general | 2848 | 2487 (87.3) | 212 (7.4) | 149 (5.2) | |
| Regional/community/rural | 2137 | 1809 (84.7) | 192 (9.0) | 136 (6.4) | |
| Private | 1060 | 927 (87.5) | 133 (12.5) | 0 (0) | |
| Diabetic | 2256 | 1882 (83.4) | 227 (10.1) | 147 (6.5) | 0.002 |
| ACS type, n (%) | <0.0001 | ||||
| STEMI | 4747 | 4314 (90.9) | 213 (4.5) | 220 (4.6) | |
| NSTE-ACS | 5251 | 4253 (81.0) | 681 (13.0) | 317 (6.0) | |
| Management strategy, n (%) | <0.0001 | ||||
| PCI only | 6572 | 6205 (94.4) | 110 (1.7) | 257 (3.9) | |
| CABG | 258 | 50 (19.4) | 179 (69.4) | 29 (11.2) | |
| Medication only | 3145 | 2292 (72.9) | 603 (19.2) | 250 (7.9) | |
| Serum creatine, mg/dL; median (IQR) | 9470 | 0.90 (0.79–1.08) | 0.93 (0.80–1.11) | 1.00 (0.83–1.20) | <0.0001 |
| Blood glucose, mg/dL; median (IQR) | 8709 | 122.0 (104–150) | 117.1 (101–151) | 124.7 (104–162) | <0.0001 |
| Haemoglobin g/dL; median (IQR) | 9358 | 14.3 (13.1–15.3) | 13.9 (12.7–15.0) | 13.9 (13.0–15.0) | 0.20 |
Forty patients with known medication history were classified as in none of the above categories.
ACS, acute coronary syndromes; CABG, coronary artery bypass graft; DAPT, dual antiplatelet therapy; NSTE-ACS, non-ST elevation acute coronary syndrome; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy; STEMI, ST-elevation myocardial infarction.